Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CT Stress myokardieperfusion, fraktionel flowreserve og angiografi hos patienter med stabile brystsmertesyndromer (DYNAMITE)

3. november 2026 opdateret af: Klaus Fuglsang Kofoed, Copenhagen University Hospital, Rigshospitalet

DYNAMISK CT-stress myokardieperfusion, CT-fraktionel flowreserve og koronar CT-angiografi til optimeret behandlingsstrategi hos patienter med stabile brystsmertesyndromer

The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.

Studieoversigt

Detaljeret beskrivelse

Trial design

The DYNAMITE trial is an investigator-initiated, randomised controlled, open-labelled trial conducted in the Capital Region of Copenhagen, Denmark

The following hypothesis will be tested:

  • First primary hypothesis: A treatment strategy guided by combined dynamic CT myocardial stress perfusion, FFR-CT and CT coronary angiography improves clinical outcome compared with a conventional management strategy in patients with chronic chest pain syndromes
  • Second primary hypothesis: A treatment strategy guided by combined dynamic CT stress myocardial perfusion, FFR-CT and CT coronary angiography results in improved symptom relief compared with a conventional management strategy in patients with chronic chest pain syndromes

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

2000

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Copenhagen, Danmark, 2100
        • Rekruttering
        • Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
        • Kontakt:
        • Underforsker:
          • Jesper J Linde, MD, Ph.D
        • Underforsker:
          • Lars V Køber, MD,DmSc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Chest pain in patients with clinically suspected or confirmed ischemic heart disease

  • Clinical indication for non-acute coronary evaluation

  • Status of coronary revascularization

    1. With previous coronary revascularization - all patients

    2. Without previous coronary revascularization

      1. Age≥65 years - all patients with chest pain

      2. Age>50 - <65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction

        • Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
        • Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease

Exclusion Criteria:

  • Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
  • Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
  • Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
  • Known severe heart failure (LVEF less than 35%)
  • Language, cultural or mental factors preventing the patient from understanding the informed consent form
  • Known atrial fibrillation
  • Known renal impairment (estimated Glomerular Filtration Rate below <30 ml/min)
  • Known x-ray contrast allergy
  • Known intolerance to adenosine infusion

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Intervention group

CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy

The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.

Ingen indgriben: Standard care group

Evaluation and treatment strategy according to contemporary clinical practice

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Major Adverse Cardiovascular Events
Tidsramme: 3 years

cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure

3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Individual components of the primary endpoint
Tidsramme: 3 years

cardiovascular death; acute myocardial infarction; stroke or hospitalization for heart failure

3 years
Acute myocardial infarction stratified by subtype
Tidsramme: 12 months

Subtypes of acute myocardial infarction according to Fourth Universal Definition 2018

12 months
Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment
Tidsramme: 3 years

Cardiovascular hospitalizations

3 years
All-cause mortality
Tidsramme: 3 years

All-cause mortality

3 years
All-cause mortality
Tidsramme: 10 years

Long-term registry based all-cause mortality at 10 years

10 years
Number and type of diagnostic tests performed
Tidsramme: 12 months

Cardiac CT, Exercise ECG, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography

12 months
Number of invasive coronary test not leading to coronary revascularization
Tidsramme: 12 months

number of invasive procedures

12 months
Number of coronary revascularization
Tidsramme: 3 years

Coronary bypass surgery and/or percutaneous coronary intervention

3 years
Cumulative iodinated contrast volume
Tidsramme: 12 months

Cardiac computed tomography, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, invasive optical coherence tomography

12 months
Cumulative radiation dose
Tidsramme: 12 months

Cardiac CT, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography

12 months
Major procedural complications occuring during procedures (invasive, non-invasive or coronary revascularization)
Tidsramme: 12 months

death, cardiac arrest, cardiac arrhytmia, acute myocardial infarction, stroke, bleeding, unplanned revascularization and any complication requiring and/or prolonging hospitalizaation at least 24 hours

12 months
Minor procedural complication specific to type of procedure (invasive, non-invasive or during coronary revascularization)
Tidsramme: 12 months

Minor procedural complications

12 months
Patients diagnosed with non-cardiac disease as likely explanation for symptoms
Tidsramme: 12 months

non-cardiac diseases causing chest pain

12 months
Seattle Angina Questionaire
Tidsramme: 3 months and 12 months

Seattle Angina Questionaire pre-randomization, 3 months and 12 months after randomization

3 months and 12 months
Quality of life by EQ-5D-5L instrument
Tidsramme: 3 months and 12 months

Quality of life estimated by EQ-5D-5L instrument pre-randomization, 3 months and 12 months after randomization

3 months and 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Klaus F Kofoed, MD, Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. december 2021

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. december 2031

Datoer for studieregistrering

Først indsendt

12. januar 2021

Først indsendt, der opfyldte QC-kriterier

12. januar 2021

Først opslået (Faktiske)

14. januar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.

IPD-delingstidsramme

Statistical Analysis Plan and study protocol a time of publication

IPD-delingsadgangskriterier

Curated by principle investigator according to contemporary law

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner